文献速递前列腺增生与排尿功能障碍

坦索罗辛治疗男性膀胱过度活动症的探索性分析

An Exploratory Analysis of Tamsulosin for Overactive Bladder (OAB) in Men With Varying Voiding Symptom Burden.
PubMed 文献 · Urology · 2021-01-20

本研究为MOTIVE试验中4周坦索罗辛0.4mg导入期的计划探索性分析,纳入116例42-88岁有尿急和尿频(>8次/24小时)的男性退伍军人。结果显示坦索罗辛显著减少排尿频率、尿急评分和夜尿次数,但基线残余尿、尿流率和AUA-7排尿症状亚评分不能预测OAB症状改善。

要点

  • 坦索罗辛0.4mg治疗4周可显著减少男性OAB患者的排尿频率、尿急评分和夜尿次数。
  • 基线AUA-7 SI总分及排尿症状亚评分类别与AUA-7 SI总分显著降低相关。
  • 基线残余尿、尿流率和AUA-7排尿症状亚评分不能预测OAB症状改善。

核心结论

  • 短期坦索罗辛治疗与男性OAB症状的统计学显著减少相关。
  • 基线残余尿、尿流率和AUA-7排尿症状亚评分不能预测坦索罗辛对OAB症状的改善。

研究设计与样本

  • 研究为MOTIVE试验中4周坦索罗辛0.4mg导入期的计划探索性分析。
  • 共纳入116例42-88岁有尿急和尿频(>8次/24小时)的男性退伍军人。

主要发现

  • 排尿频率从11.3次/24小时降至10.0次/24小时(P<.0001)。
  • 尿急评分从平均2.5分降至2.2分(P<.0001)。
  • 夜尿次数从2.1次降至1.8次(P<.001)。
  • 仅基线AUA-7 SI总分和排尿症状亚评分类别(轻、中、重)与AUA-7 SI总分显著降低相关。
  • 连续变量中仅基线AUA-7 SI总分与AUA-7 SI储尿症状变化相关。

关键数值与推荐

  • 坦索罗辛剂量为0.4mg,治疗持续4周。
  • OAB入选标准为尿急和尿频(>8次排尿/24小时)。
  • AUA-7 SI总分及排尿症状亚评分分为轻度、中度、重度三类。

临床怎么用

  • 对于男性OAB患者,可考虑短期使用坦索罗辛0.4mg以改善排尿频率、尿急和夜尿。
  • 基线残余尿、尿流率和AUA-7排尿症状亚评分不宜用于预测坦索罗辛对OAB症状的疗效。

局限性

  • 本研究为探索性分析,结果需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate tamsulosin (α-blocker therapy) for male overactive bladder (OAB) and to examine if indicators of concomitant benign prostatic hyperplasia are associated with OAB symptom improvement. MATERIALS AND METHODS: This was a planned, exploratory analysis of a 4-week, α-blocker (tamsulosin 0.4 mg) run-in phase of the Male Overactive Bladder Trial in Veterans (MOTIVE). Participants with urinary urgency and urinary frequency (> 8 voids/24 hours) completed bladder diaries, answered symptom questionnaires (AUA-7 SI), and had post-void residual and noninvasive uroflowmetry measurement. RESULTS: A total of 116 male Veterans aged 42-88 years with OAB participated. There were statistically significant reductions in voiding frequency (11.3 > 10.0 voids/24 hours, P < .0001), urgency scores (mean 2.5-2.2 points, P < .0001), and nightly nocturia (2.1 > 1.8, P < .001). Only baseline AUA-7 SI total and voiding subscale categories (mild, moderate, severe) were associated with significant reduction in AUA-7 SI total score. For continuous variables, only AUA-7 SI baseline total score was associated with AUA-7 SI storage symptom changes. No other baseline measures were associated with changes in urgency, frequency, or nocturia. CONCLUSION: Initiation of short course tamsulosin therapy in men was associated with statistical reduction in OAB symptoms. Baseline post-void residual, uroflow rate, and the voiding symptom subscore of the AUA-7 SI were not predictive of OAB symptom improvement with tamsulosin. These findings merits further exploration.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Johnson TM, Goode PS, Hammontree L, et al. An Exploratory Analysis of Tamsulosin for Overactive Bladder (OAB) in Men With Varying Voiding Symptom Burden. Urology. 2021. PMID: 33482134. doi:10.1016/j.urology.2021.01.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。